Prab at 17:17, 22 March 2025

2025-03-22T17:17:51Z

← Older revision		Revision as of 17:17, 22 March 2025
Line 67:		Line 67:
	[[Category:Drugs]]		[[Category:Drugs]]
	{{No image}}		{{No image}}
	~~__NOINDEX__~~

Prab: CSV import

2025-03-17T23:10:15Z

CSV import

← Older revision		Revision as of 23:10, 17 March 2025
Line 67:		Line 67:
	[[Category:Drugs]]		[[Category:Drugs]]
	{{No image}}		{{No image}}
			__NOINDEX__

Prab: CSV import

2025-02-10T20:50:08Z

CSV import

← Older revision		Revision as of 20:50, 10 February 2025
Line 66:		Line 66:
	[[Category:Pharmaceuticals]]		[[Category:Pharmaceuticals]]
	[[Category:Drugs]]		[[Category:Drugs]]
			{{No image}}

Prab at 12:22, 27 August 2023

2023-08-27T12:22:59Z

New page

'''Polycap''' is a groundbreaking [[fixed dose combination]] (FDC) [[polypill]], developed by [[Cadila Pharmaceuticals Limited]], an esteemed pharmaceutical company based in [[Ahmedabad]], [[India]]. This unique pill integrates moderate quantities of five distinct medications, targeting the prevention and reduction of [[myocardial infarction|heart attacks]] and [[stroke]]s.

=== Composition and Mechanism ===

Polycap is meticulously designed to combine the following components:

* Three blood pressure-regulating drugs.
* A cholesterol reducer.
* [[Aspirin]].

Significantly, a 2009 study illuminated the potential of this combination, revealing a 50% reduction in the risk of heart attacks and strokes, compared to individuals who consumed each component separately. Impressively, there was no escalation in [[adverse effect]]s<ref name=Record>Marchione, Marilynn via ''[[Associated Press]]''. [http://www.northjersey.com/news/nation/42172847.html "Study says one combo pill does work of five"], ''[[The Record (Bergen County)]]'', March 31, 2009. Accessed March 31, 2009.</ref>.

=== The Concept of Fixed Dose Combinations (FDCs) ===

The idea of FDCs like Polycap has burgeoned in popularity, particularly with the appeal of minimizing the "pill burden" many patients experience. However, there's a double-edged sword: while FDCs might alleviate the mental stress of consuming multiple pills, they might not cater optimally to individual patient needs, potentially giving them superfluous or inadequate drug components.

Initially, Wald and Law postulated a six-drug concoction to be administered to patients over the age of 55 with increased risk of [[cardiovascular disease]] events. This would encompass:

* Three half-dose [[antihypertensive]]s drugs.
* [[Aspirin]].
* A [[statin]].
* [[Folic acid]].

Notably, after rigorous scrutiny showing no enhancement in patient outcomes with folic acid, it was consequently excluded from the Polycap by Cadila Pharmaceuticals.

As of now, "Polycap" amalgamates:

* 100mg of aspirin.
* 20mg of [[simvastatin]] (a cholesterol-reducing statin equivalent to Zocor).
* Lower doses of blood pressure medications: [[atenolol]] (50mg), [[ramipril]] (5mg), and [[thiazide]] (12.5mg).

This multifaceted pill retains a compact size, ensuring ease of consumption<ref name=Record/>.

=== The Indian Polycap Study (TIPS) ===

[[Cadila Pharmaceuticals Limited]] sponsored a pivotal study titled "The Indian Polycap Study (TIPS)". Coordinated by JP Parswani and Dr. Arun Maseeh, this study was meticulously helmed by Dr. Salim Yusuf from [[McMaster University]], [[Hamilton, Ontario]], and Dr. Prem Pais from [[St. John's Medical College]], [[Bangalore]], India.

This double-blind, controlled study delved into the effects of Polycap on 2,000 participants (average age 54). All participants exhibited at least one cardiovascular risk factor, such as [[diabetes]], [[hypercholesterolemia]], [[hypertension]], [[obesity]], or [[smoking]]<ref name=Record/>.

During a 12-week period:

* 400 participants consumed Polycap.
* The rest were classified into eight groups, consuming either individual components or a combination thereof<ref name=Record/>.

Those administered Polycap experienced a six to seven-point decrease in both systolic and diastolic [[blood pressure]] levels, thus hinting at a considerable reduction in heart disease and stroke risks<ref name=Record/>.

=== Polycap PK Study ===

Conducted by Dr. Bhaswat Chakraborty and his team, the Polycap PK study confirmed the efficacy of Polycap in reducing multiple cardiovascular risks, along with ensuring the bioavailability of each of its components and nullifying potential drug-drug interactions<ref name=PK>Preservation of Bioavailability of Ingredients and Lack of Drug-drug Interactions in a Novel Five Ingredient Polypill (PolycapTM) in a Five Arm Phase-I Crossover Trial in Healthy Volunteers, by Anil Patel, et al, Am. J. Cardiovasc. Drugs, 10: 95-103.</ref>.

== Conclusion ==

'''Polycap''' signifies a revolutionary step in cardiovascular medication. While still necessitating comprehensive and global acceptance and distribution, it embodies the potential to reshape how cardiovascular risks are managed, especially in regions where pill burden is a pertinent concern.

== See Also ==
* [[Cadila Pharmaceuticals Limited]]
* [[Myocardial infarction]]
* [[Stroke]]
* [[Antihypertensive]]
* [[Fixed dose combination]]
== External links ==
* [http://clinicaltrials.gov/ct2/show/NCT00443794 The Indian POLYCAP Study (TIPS)]
* [http://www.cadilapharma.com Cadila Pharmaceuticals Limited]
* [http://polycapcpl.blogspot.com/2009/04/first-look.html The actual size "zero" capsule used in The Indian Polycap Study]
{{stub}}
[[Category:Pharmaceuticals]]
[[Category:Drugs]]

Polycap - Revision history

Prab at 17:17, 22 March 2025

Prab: CSV import

Prab: CSV import

Prab at 12:22, 27 August 2023